2026-10-25
Schrödinger, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,990 +1.35%
S&P 7,377 +0.31%
GOLD $4,075 −0.94%
BTC $75,677 −0.09%
VIX 25.64 −9.01%
latest tape · as of 20:08 UTC
The Screen · Healthcare · Health Information Services
Schrödinger, Inc.
SDGR · Nasdaq · USD · Market cap $2.2B · 850 employees
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pa…
Not yet scored29.82 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price29.82 USD at the 6 Nov 2026 close
- Our value readFair vs our fair value, as of 6 Nov 2026
- Our regime readMarkup, as of 7 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.21)
- Last reviewed6 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $17.00 to $32.00, base estimate $30.00 (screen dated 2026-11-06).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.21, read 2026-11-05
- Ethical screen not yet scored
Price29.82 USD
Fair value30.00
Ethical score70.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-11-01Read Markup27.14+9.9% to today ✓Distribution gives way to Markup after a 7% rise in 11 days
2026-10-21Read Distribution25.48+17.0% to today Markup gives way to Distribution after a 66% rise in 10 weeks
2026-08-12Read Markup15.32+94.6% to today ✓Accumulation gives way to Markup after a 6% rise in 6 weeks
2026-07-02Read Accumulation14.45+106.4% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Schrödinger, Inc. holds its Markup at $29.82. Consolidating, no directional conviction, held for 2 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 2 days |
| Price at the screen | $29.82 |
| Valuation | N/A trailing · -21.31 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 1.65 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 15.04% | Below 33% | Interest-bearing debt is just 15.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 22.71% | Below 33% | Cash held in interest-bearing accounts and securities is 22.7% of assets, under the one-third limit. | Pass |
| Receivables | 43.18% | Below 49% | Money owed to the company is 43.2% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Schrödinger, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Schrödinger, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 15%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 4% discount to our $30.00 fair value, 7.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 0.6% discount to the base estimate.
Third-party analyst targets: 7 covering, consensus Buy. The average target sits +1% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & ProjectionsWhere our models see it going: fair-value estimate $30.00, with a range of $17.00 to $32.00, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsSoftware that hunts molecules still burns cash
Schrödinger sells a physics-based platform meant to cut the cost and time of finding new drug and materials molecules. Think of it as a digital wind tunnel for chemistry that big pharma and materials firms can licence. Yet revenue fell 2 percent last year while the firm posted a 41 percent negative profit margin and negative 30 percent return on equity, so the business is still losing money at scale.
We pass despite the shares trading at a 30 percent discount to our 20 dollar fair value and a forward multiple of negative 9.2 times. The opportunity rating sits at none because the company has no proven moat, growth has turned negative, and seven analysts already cluster around the same 20 dollar target. Ethical screens clear, but that alone does not create an investable edge.
Risk sits in execution and cash burn. Continued losses could force dilution or slow platform adoption if customers stick with traditional wet-lab methods. Currency moves and funding cycles in biotech add further swings. Analysis, not advice.
| Forward P/E | -21.3x |
| EPS, trailing | -0.74 |
| EPS, forward | -1.35 |
| Revenue growth | +7.5%slow but positive growth |
| Profit margin | -21.0%currently unprofitable |
| Return on equity | -16.2%not currently earning a positive return on equity |
| FCF yield | -1.36% |
| Debt to equity | 0.33minimal debt: a conservative balance sheet |
| Current ratio | 2.71comfortably covers its short-term bills |
| Beta | 1.65much more volatile than the market |
| Short interest, float | 0.25% |
| 52-week range | 10.95 - 33.78 |
| Market cap | $2.2B |
| Employees | 850 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSDGR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-04
Markup $27.18
+0.1% Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Markup $27.14
+0.0% Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Markup $27.14
+0.0% Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Markup · changed $27.14
+14.0% Entry 13
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Distribution $23.80
+0.0% Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Distribution $23.80
+0.0% Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Distribution $23.80
+5.3% Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Distribution $22.60
-11.3% Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21. Since the last review it entered the Titan Ethical 500; its composite score rose. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Distribution · changed $25.48
-6.6% Entry 8
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21.
2026-10-14
Markup $27.28
-9.8% Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (8 analysts) rates it none, with a mean price target of $21.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- iRhythm Holdings, Inc. (IRTC) Earnings Expected to Grow: Should You Buy? Yahoo Finance · 9d ago
- Schrödinger (SDGR) Stock Sees Fair Value Lift As AI Optimism Lifts Analyst Targets Yahoo Finance · 10d ago
- Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline Yahoo Finance · 10d ago
- Schrödinger to Present at UBS Global Healthcare Conference Yahoo Finance · 10d ago
- Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance · 12d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
OMCLOmnicell, Inc.
CERTCertara, Inc.
OMDAOmada Health, Inc.
TDOCTeladoc Health, Inc.
HSTMHealthstream Inc
PRVAPrivia Health Group, Inc.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $12.72 | +11.2% | · | $1,112 | +11.2% |
| 2 months | $11.37 | +24.5% | · | $1,245 | +24.5% |
| 3 months | $12.16 | +16.4% | · | $1,164 | +16.4% |
| 6 months | $18.13 | -22.0% | · | $781 | -22.0% |
| 1 year | $26.13 | -45.9% | · | $542 | -45.9% |
| 2 years | $21.35 | -33.7% | · | $663 | -33.7% |
| 3 years | $36.64 | -61.4% | · | $386 | -61.4% |
| 5 years | $77.51 | -81.7% | · | $183 | -81.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SDGR does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.